Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

Abstract:

:We conducted a phase 2 study with bortezomib, doxorubicin, and dexamethasone (PAD) followed by thalidomide and dexamethasone (TD) in patients with relapsed multiple myeloma (MM). Forty patients were enrolled between November 2005 and October 2007, with follow-up continuing until January 2009. Efficacy could be assessed in 37 patients. The overall response rate to PAD followed by TD was 83.6%: complete response 51.4%, near-complete response 13.4%, very good partial remission 5.4%, and partial response 13.4%. The median follow-up was 27 months (range 13-39). The median progression-free survival (PFS) from the start of treatment was 18 months (95% CI, 9.7-26.2 months), with a 1-year PFS rate of 56.9% and 3-year PFS rate of 25.7%. Median overall survival was 35.1 months (95% CI, 18.5-51.7), with a 1-year survival rate of 75% and 3-year survival rate of 27.3%. One hundred seventy-eight PAD cycles (median 6, range 1-6) in 38 patients were assessable for safety. The most common hematologic toxicity was thrombocytopenia, with grade 3-4 in 35.8%. Sensory neuropathy occurred at grade 2 in 26.3% and grade 3 in 10.3%. Two hundred TD treatment cycles (median 4, range 0-12 cycles) were administered. Most adverse events were of mild degree and manageable. PAD followed by TD in patients with relapsed MM is very effective and tolerable.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Lee SS,Suh C,Kim BS,Chung J,Joo YD,Ryoo HM,Do YR,Jin JY,Kang HJ,Lee GW,Lee MH,Shim H,Kim K,Yoon SS,Bang SM,Kim HY,Lee JJ,Park J,Lee DS,Lee JH,Korean Multiple Myeloma Working Party.

doi

10.1007/s00277-010-0943-z

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

905-12

issue

9

eissn

0939-5555

issn

1432-0584

journal_volume

89

pub_type

杂志文章,多中心研究
  • Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation.

    abstract::Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a low survival outcome and a high non-relapse mortality (NRM) rate which is a major obstacle to this treatment. We hypothesized that the status of malnourishment after first allo-HSCT as represented by the geriatric nutritional risk index (GNRI)...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-04089-0

    authors: Kaito S,Wada A,Adachi H,Konuma R,Kishida Y,Nagata A,Konishi T,Yamada Y,Kumagai T,Yoshifuji K,Mukae J,Akiyama M,Inamoto K,Toya T,Igarashi A,Najima Y,Muto H,Kobayashi T,Kakihana K,Ohashi K,Sakamaki H,Doki N

    更新日期:2020-07-01 00:00:00

  • Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.

    abstract::Patients with primary refractory or relapsed acute myeloid leukemia (AML) who undergo intensive salvage chemotherapy carry a high risk of treatment failure due to infectious complications and early relapses. The study presented here assessed the effect of granulocyte colony-stimulating factor (G-CSF) on the duration o...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002770050425

    authors: Kern W,Aul C,Maschmeyer G,Kuse R,Kerkhoff A,Grote-Metke A,Eimermacher H,Kubica U,Wörmann B,Büchner T,Hiddemann W

    更新日期:1998-09-01 00:00:00

  • Autoimmune hemolytic anemia in patients with de novo acute myelocytic leukemia.

    abstract::Autoantibody against erythrocytes has occasionally been observed in patients with de novo acute myelocytic leukemia (AML). However, it is not clear whether this autoantibody in AML patients induces frank hemolysis (autoimmune hemolytic anemia, AIHA), as seen in lymphoid neoplasms. We present two de novo AML patients w...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF00663016

    authors: Tamura H,Ogata K,Yokose N,An E,Kamikubo K,Dan K,Kajii E,Nomura T

    更新日期:1996-01-01 00:00:00

  • The presence of CD28-negative T cells in a patient with multicentric Castleman's disease.

    abstract::We found increased numbers of CD28-negative T cells in a patient with multicentric Castleman's disease (MCD), who also had significantly decreased interleukin-2 (IL-2) production and impaired T-cell proliferation. The presence of CD28-negative T cells may be indicative of a functional T-cell defect in MCD. ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050228

    authors: Ishiyama T,Koike M,Kakimoto T,Akimoto Y,Tsuruoka N

    更新日期:1996-10-01 00:00:00

  • Relapsing bloodstream infections during treatment of acute leukemia.

    abstract::Acute leukemia (AL) patients may experience more than one episode of bloodstream infection (BSI) caused by the same pathogen during the entire chemotherapy program. In order to identify factors influencing BSI recurrence (R-BSI) during subsequent phases of treatment, we analyzed all BSIs occurring to consecutively tre...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-013-1965-0

    authors: Cattaneo C,Antoniazzi F,Tumbarello M,Skert C,Borlenghi E,Schieppati F,Cerqui E,Pagani C,Petullà M,Re A,Rossi G

    更新日期:2014-05-01 00:00:00

  • Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.

    abstract::The impact of intraocular involvement (IOL) in primary CNS lymphoma (PCNSL) has not been sufficiently evaluated. Here, we present the analysis of IOL in the only completed randomized phase III trial in PCNSL. The G-PCNSL-SG1 study evaluated the role of whole-brain radiotherapy in primary therapy of PCNSL. Data of the ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00277-014-2212-z

    authors: Kreher S,Strehlow F,Martus P,Roth P,Hertenstein B,Röth A,Birnbaum T,Griesinger F,Rauch M,Kanz L,Thiel E,Weller M,Korfel A

    更新日期:2015-03-01 00:00:00

  • Pregnancy in patients with thalassemia major: a cohort study and conclusions for an adequate care management approach.

    abstract::An improvement in quality of life and survival occurred among thalassemia major (TM) patients: pregnancy in such patients has become a reality. Safe pregnancy and delivery require efforts to ensure the best outcomes. Between 2007 and 2016, 30 TM patients had 37 pregnancies. We analyzed the hematological parameters bef...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-2979-9

    authors: Cassinerio E,Baldini IM,Alameddine RS,Marcon A,Borroni R,Ossola W,Taher A,Cappellini MD

    更新日期:2017-06-01 00:00:00

  • Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark.

    abstract::We conducted a nationwide cohort study of adult Danish patients with primary chronic immune thrombocytopenia (cITP) to examine selected patient and clinical characteristics as predictors for splenectomy. We analyzed data from the Danish National Patient Registry and patient medical records from 1996 to 2007. Using Cox...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1047-5

    authors: Jensen AO,Nørgaard M,Engebjerg MC,Farkas DK,Fryzek JP,Zhao S,Sørensen HT

    更新日期:2011-02-01 00:00:00

  • Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.

    abstract::In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00277-016-2638-6

    authors: Gratwohl A,Iacobelli S,Bootsman N,van Biezen A,Baldomero H,Arcese W,Arnold R,Bron D,Cordonnier C,Ernst P,Ferrant A,Frassoni F,Gahrton G,Richard C,Kolb HJ,Link H,Niederwieser D,Ruutu T,Schattenberg A,Schmitz N,Torr

    更新日期:2016-05-01 00:00:00

  • Anti-phospholipid antibodies bind to platelet microparticles in idiopathic (autoimmune) thrombocytopenic purpura.

    abstract::We recently reported that IgM antibody-related microparticles exist in some patients with idiopathic thrombocytopenic purpura (ITP) [14]. In this study, we investigated the relationship between antiphospholipid (cardiolipin and phosphatidylinositol) antibodies and microparticles in 56 ITP patients. We used an ELISA to...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01715126

    authors: Nomura S,Yanabu M,Fukuroi T,Kido H,Kawakatsu T,Yamaguchi K,Suzuki M,Kokawa T,Yasunaga K

    更新日期:1992-07-01 00:00:00

  • Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis.

    abstract::We have performed a retrospective analysis of all patients with extragastric mucosa-associated lymphoid tissue (MALT) lymphoma treated at our institution to compare the efficacy of first-line therapeutic modalities including surgery, radiation, systemic therapy, and antibiotics. One hundred eighty-five patients with e...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2042-z

    authors: Wöhrer S,Kiesewetter B,Fischbach J,Müllauer L,Troch M,Lukas J,Mayerhoefer ME,Raderer M

    更新日期:2014-08-01 00:00:00

  • Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families.

    abstract::In Germany, analyses of clinical and laboratory features of patients with acute porphyrias are only available for hereditary coproporphyria (HCP) but not with other acute porphyrias, acute intermittent porphyria (AIP) and variegate porphyria (VP). The aim of the study was to analyze a large cohort of patients with par...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-019-03831-7

    authors: Bronisch O,Stauch T,Haverkamp T,Beykirch MK,Petrides PE

    更新日期:2019-12-01 00:00:00

  • Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.

    abstract::Polo-like kinase 2 (SNK/PLK2), a transcriptional target for wild-type p53 and is hypermethylated in a high percentage of multiple myeloma and B cell lymphomas patients. Given these data, we sought to study the methylation status of the specific gene in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1193-4

    authors: Benetatos L,Dasoula A,Hatzimichael E,Syed N,Voukelatou M,Dranitsaris G,Bourantas KL,Crook T

    更新日期:2011-09-01 00:00:00

  • B cell-activating factor: its clinical significance in multiple myeloma patients.

    abstract::B cell-activating factor (BAFF) is a cytokine that plays a major role in the maintenance of normal B-cell development and homeostasis. It has been suggested that in multiple myeloma (MM) it might have regulatory effects on the proliferation and viability of malignant plasma cells. The aim of this study was to evaluate...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-012-1470-x

    authors: Fragioudaki M,Boula A,Tsirakis G,Psarakis F,Spanoudakis M,Papadakis IS,Pappa CA,Alexandrakis MG

    更新日期:2012-09-01 00:00:00

  • MCNU in the treatment of essential thrombocythemia--a pilot study.

    abstract::The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). As the platelet counts increased during the following 4 weeks, an extra dose of 100 mg of MCNU was administered to three patients. All patients had thrombotic or hemorrhagic complications. Seven...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01738474

    authors: Murakami H,Tamura J,Sawamura M

    更新日期:1993-05-01 00:00:00

  • Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.

    abstract::Autologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma (NHL). However, recent supply issues and toxicity of carmustine have necessitated a new conditioning regimen. We conducted a multicenter, phase II study of BEB (busulfan, etoposide, and bendamustine) conditioning regimen for ASCT...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-020-03942-6

    authors: Kim DY,Chung JS,Jo JC,Cho SH,Shin HJ

    更新日期:2020-04-01 00:00:00

  • A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.

    abstract::Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0718-x

    authors: Gholam D,Vantelon JM,Al-Jijakli A,Bourhis JH

    更新日期:2003-12-01 00:00:00

  • Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.

    abstract::To investigate whether cytokine genetic polymorphisms influence the outcome of diffuse large B cell lymphoma (DLBCL), we tested 337 consecutive DLBCL treated with CHOP or rituximab-CHOP (R-CHOP) from interleukin 10 (IL10), Bcl-2, and tumor necrosis factor (TNF)-α polymorphisms. Patients who carried the IL10 rs1800871 ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2857-x

    authors: Liu D,Wang Y,Dong M,Guan S,Wang Y,Sun H,Wu N,Li S,Bai J,Chen F,Sun D,Jin Y

    更新日期:2017-02-01 00:00:00

  • Hydroxyurea in thalassemia intermedia--a promising therapy.

    abstract::Pharmacological agents such as hydroxyurea (HU) have been known to cause induction of fetal hemoglobin and possibly may alleviate the symptoms in thalassemia intermedia patients. Thirty-seven patients with beta-thalassemia intermedia were enrolled to assess response to HU therapy. Major response was defined as transfu...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-005-1026-4

    authors: Dixit A,Chatterjee TC,Mishra P,Choudhry DR,Mahapatra M,Tyagi S,Kabra M,Saxena R,Choudhry VP

    更新日期:2005-07-01 00:00:00

  • Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.

    abstract::Evaluation of bone marrow involvement (BMI) by conventional bone marrow biopsy (BMB) can generate false-negative results if marrow disease is focal. The sensitivity of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) in assessing BMI in extranodal NK/T cell lymphoma (ENKL) h...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2289-4

    authors: Zhou Z,Chen C,Li X,Li Z,Zhang X,Chang Y,Lu L,Cui Y,Ma Y,Zhang M

    更新日期:2015-06-01 00:00:00

  • Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.

    abstract::Mixed phenotype acute leukemia (MPAL) is a rare type of leukemia with a limited number of studies conducted to characterize its clinical spectrum and most importantly the best treatment modality. MPAL blasts show more than one phenotype either myeloid/monocytic with T- or B-lymphoid or extremely rare triple lineage as...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-04354-2

    authors: Rasekh EO,Osman R,Ibraheem D,Madney Y,Radwan E,Gameel A,Abdelhafiz A,Kamel A,Elfishawi S

    更新日期:2020-11-23 00:00:00

  • DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.

    abstract::A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezom...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00277-009-0726-6

    authors: Kropff M,Liebisch P,Knop S,Weisel K,Wand H,Gann CN,Berdel WE,Einsele H,Deutsche Studiengruppe Multiples Myelom, DSMM.

    更新日期:2009-11-01 00:00:00

  • Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study.

    abstract::The general objective of this study was to evaluate the risks of agranulocytosis and aplastic anemia in relation to drug use. Other potential risk factors, including history of infectious mononucleosis, were also evaluated. In an international population-based case-control study, cases of agranulocytosis and aplastic ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01695866

    authors: Levy M,Kelly JP,Kaufman DW,Shapiro S

    更新日期:1993-10-01 00:00:00

  • Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.

    abstract::Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are interrelated ultra-rare diseases. Quality of life (QoL) evaluation tools used in studies for AA and PNH are unspecific and designed for cancer patients (e.g., the European Organization for Research and Treatment of Cancer Quality of Life Q...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2867-8

    authors: Groth M,Singer S,Niedeggen C,Petermann-Meyer A,Röth A,Schrezenmeier H,Höchsmann B,Brümmendorf TH,Panse J

    更新日期:2017-02-01 00:00:00

  • The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion.

    abstract::The absence of researches about autophagy in multiple myeloma promoted us to explore the biological characteristics and role of autophagy induced by nutrient depletion in multiple myeloma (MM) cell line RPMI8226 cells. Both autophagic and apoptotic morphology were observed by TUNEL, transmission electron microscopy (T...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1315-z

    authors: Zeng R,He J,Peng J,Chen Y,Yi S,Zhao F,Cui G

    更新日期:2012-03-01 00:00:00

  • Biotherapy of chronic myelogenous leukemia.

    abstract::The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML. In additi...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/BF01682030

    authors: Aulitzky WE,Peschel C,Schneller F,Huber C

    更新日期:1995-03-01 00:00:00

  • Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.

    abstract::Early cytomegalovirus (CMV) replication (eCMV) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been suggested as an independent factor that reduces leukemia relapse risk. We retrospectively analyzed 74 patients with acute myeloid leukemia (AML) who underwent allo-HSCT between August 2006 and S...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2190-1

    authors: Jang JE,Kim SJ,Cheong JW,Hyun SY,Kim YD,Kim YR,Kim JS,Min YH

    更新日期:2015-02-01 00:00:00

  • Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.

    abstract::To investigate the problem of allogeneic bone marrow transplantation (allo-BMT) for advanced stage patients, we retrospectively analyzed 24 consecutive patients who underwent allo-BMT in the non-remission stage. Twenty-four patients (19 males and 5 females) with acute leukemia, chronic myelogenous leukemia, and malign...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-002-0506-z

    authors: Tabata M,Satake A,Okura N,Yamazaki Y,Toda A,Nishioka K,Tanaka H,Chin M,Itsukuma T,Yamaguchi M,Misawa M,Kai S,Hara H

    更新日期:2002-10-01 00:00:00

  • Polymorphisms of interleukin-1 gene complex, IL6 and tumour necrosis factor genes in chronic idiopathic neutropenia of adults.

    abstract::Chronic idiopathic neutropenia of adults (CINA) is a granulocytic disorder characterised by the "unexplained" decrease in the number of circulating neutrophils. Serum inflammatory cytokines and chemokines are increased in CINA. In addition, cytokines gene polymorphisms are associated with increased levels of respectiv...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-005-1066-9

    authors: Addas-Carvalho M,de Paula EV,Lima CS,Saad ST

    更新日期:2005-10-01 00:00:00

  • Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.

    abstract::Established risk factors for thrombosis in essential thrombocythemia (ET) include age (≥ 60 years) and previous vascular events. Recently, also leukocytosis has been proposed in risk stratification of ET patients. We report a retrospective study on 532 ET patients followed for a median of 7.6 years. Sixty-four patient...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1154-3

    authors: Palandri F,Polverelli N,Catani L,Ottaviani E,Baccarani M,Vianelli N

    更新日期:2011-08-01 00:00:00